AFP and Cirrhosis: To further explore the performance of the immunodiagnostic model and AFP in distinguishing HCC from at‐risk patients, we set up an at‐risk control group which included 96 chronic hepatitis B sera and 157 cirrhosis sera, as well as all 380 HCC sera and 380 NC sera from both training and validation sets in this study.